These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2876511)

  • 1. Human pharmacological effects of SMS 201-995 on gastric secretion.
    Gyr KE; Whitehouse I; Beglinger C; Köhler E; Dettwiler S; Fried M
    Scand J Gastroenterol Suppl; 1986; 119():96-102. PubMed ID: 2876511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of an octapeptide somatostatin analogue (SMS 201-995) and somatostatin-14 (SST-14) on pentagastrin-stimulated gastric acid secretion: a comparative study in man.
    Whitehouse I; Beglinger C; Fried M; Gyr K
    Hepatogastroenterology; 1984 Oct; 31(5):227-9. PubMed ID: 6150888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of pentagastrin-stimulated acid secretion after subcutaneous administration of a new somatostatin analogue.
    Whitehouse I; Beglinger C; Rüttimann G; Gyr K
    Gut; 1986 Feb; 27(2):141-6. PubMed ID: 2868973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of meal stimulated gastric acid secretion by an octapeptide somatostatin analogue SMS 201-995.
    Olsen JA; Loud FB; Christiansen J
    Gut; 1987 Apr; 28(4):464-7. PubMed ID: 2884171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMS 201-995-induced stimulation of gastric acid secretion via the dorsal vagal complex and inhibition via the hypothalamus in anaesthetized rats.
    Yoneda M; Taché Y
    Br J Pharmacol; 1995 Oct; 116(4):2303-9. PubMed ID: 8564264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged inhibition of meal-stimulated acid secretion and gastrin release following single subcutaneous administration of octreotide (SMS 201-995) in man.
    Karnes WE; Maxwell V; Sytnik B; Chew P; Walsh JH
    Aliment Pharmacol Ther; 1989 Dec; 3(6):527-38. PubMed ID: 2518866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide (SMS 201-995).
    Kemmer TP; Malfertheiner P; Büchler M; Friess H; Meschenmoser L; Ditschuneit H
    Aliment Pharmacol Ther; 1992 Feb; 6(1):41-50. PubMed ID: 1371938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of adding albumin to solutions of somatostatin (SST-14) on inhibiting pentagastrin-stimulated acid secretion in man.
    Whitehouse I; Beglinger C; Bally H; Gyr K
    Digestion; 1986; 33(2):69-73. PubMed ID: 2868953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a new somatostatin analogue on pancreatic function in healthy volunteers.
    Köhler E; Beglinger C; Dettwiler S; Whitehouse I; Gyr K
    Pancreas; 1986; 1(2):154-9. PubMed ID: 2437563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men.
    Lembcke B; Creutzfeldt W; Schleser S; Ebert R; Shaw C; Koop I
    Digestion; 1987; 36(2):108-24. PubMed ID: 2883060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of somatostatin analogue octreotide injected into the third cerebral ventricle on pentagastrin-induced gastric acid secretion in rats.
    Gao F; Hu XF
    World J Gastroenterol; 2006 May; 12(17):2767-9. PubMed ID: 16718766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of somatostatin analogue (SMS 201-995, Sandostatin) on pancreatic secretion in humans.
    Creutzfeldt W; Lembcke B; Fölsch UR; Schleser S; Koop I
    Am J Med; 1987 May; 82(5B):49-54. PubMed ID: 2884879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of SMS 201-995, a somatostatin analogue, on the exocrine pancreatic secretion and gut hormone release in dogs.
    Misumi A; Shiratori K; Lee KY; Barkin JS; Chey WY
    Surgery; 1988 Apr; 103(4):450-5. PubMed ID: 2895501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central action of somatostatin analog, SMS 201-995, to stimulate gastric acid secretion in rats.
    Yoneda M; Raybould H; Taché Y
    Peptides; 1991; 12(3):401-6. PubMed ID: 1923921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastric secretion and gastrin under progressive doses of somatostatin-14 and -28 administered intraperitoneally to the rat.
    Seefried G; Schmidtler J; Schwille PO
    Peptides; 1988; 9(2):249-55. PubMed ID: 2897678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of SMS 201-995 on basal and stimulated pancreatic secretion in rats.
    Guan D; Maouyo D; Sarfati P; Morisset J
    Endocrinology; 1990 Jul; 127(1):298-304. PubMed ID: 2361474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.
    Harris AG
    Gut; 1994; 35(3 Suppl):S1-4. PubMed ID: 7911441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inhibitory effect of octreotide on exocrine pancreatic secretion in conscious dogs.
    Suzuki T; Naruse S; Yanaihara N
    Pancreas; 1993 Mar; 8(2):226-32. PubMed ID: 8096338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effect of somatostatin and an analogue, SMS 201-995, on gastrin and insulin secretion from isolated perfused rat stomach and pancreas.
    Takemura J; Kwok YN; Brown JC
    Am J Med; 1986 Dec; 81(6B):65-73. PubMed ID: 2879449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analog, SMS 201-995, inhibits pancreatic exocrine secretion and release of secretin and cholecystokinin in rats.
    Shiratori K; Watanabe S; Takeuchi T
    Pancreas; 1991 Jan; 6(1):23-30. PubMed ID: 1704631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.